Risk factor
Low price volatility
Profitability factor
Decent price performance
About
Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of BIOCON.NS is 437 and suggests 5% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati